This Week in Lancet Oncology


In Lancet Oncology this week, researchers in France present results from a Phase II trial of an attenuated immunochemotherapy treatment for patients older than 80 with diffuse large B-cell lymphoma. The researchers aimed to investigate the efficacy and safety of a decreased dose of CHOP chemotherapy, a combination of doxorubicin, cyclophosphamide, vincristine, and prednisone, with a conventional dose of rituximab.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.